FR2841781A1 - Cosmetic or dermatological composition, e.g. for promoting wound healing and skin regeneration, comprises a peptide including a Leu-Asp-Ala-Pro sequence - Google Patents

Cosmetic or dermatological composition, e.g. for promoting wound healing and skin regeneration, comprises a peptide including a Leu-Asp-Ala-Pro sequence Download PDF

Info

Publication number
FR2841781A1
FR2841781A1 FR0208285A FR0208285A FR2841781A1 FR 2841781 A1 FR2841781 A1 FR 2841781A1 FR 0208285 A FR0208285 A FR 0208285A FR 0208285 A FR0208285 A FR 0208285A FR 2841781 A1 FR2841781 A1 FR 2841781A1
Authority
FR
France
Prior art keywords
peptide
ala
leu
asp
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0208285A
Other languages
French (fr)
Other versions
FR2841781B1 (en
Inventor
Farra Claude Dal
Nouha Domloge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vincience SA
Original Assignee
Vincience SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vincience SA filed Critical Vincience SA
Priority to FR0208285A priority Critical patent/FR2841781B1/en
Publication of FR2841781A1 publication Critical patent/FR2841781A1/en
Application granted granted Critical
Publication of FR2841781B1 publication Critical patent/FR2841781B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cosmetic or dermatological composition for promoting wound healing and skin regeneration or for enhancing cellular regeneration and extracellular matrix protein synthesis comprises a peptide (I) including a Leu-Asp-Ala-Pro sequence. An independent claim is also included for a cosmetic method for promoting wound healing and skin regeneration or for enhancing extracellular matrix molecule expression, comprising applying the above composition to the skin. ACTIVITY : Vulnerary. No biological data given. MECHANISM OF ACTION : None given.

Description

La présente invention se rapporte à l'utilisation pour la préparationThe present invention relates to the use for the preparation

d'une composition, d'une quantité efficace de peptides de séquence (AA)nLeu-Asp-Ala-Pro-(AA)n, dans laquelle AA est un quelconque acide aminé ou un de ses dérivés, n est compris entre 0 et 2, et o les acides aminés peuvent être sous la forme L, D ou DL; les peptides ou la composition étant destinés à favoriser la cicatrisation et la régénération cutanée, et à  of a composition, of an effective amount of peptides of sequence (AA) nLeu-Asp-Ala-Pro- (AA) n, in which AA is any amino acid or one of its derivatives, n is between 0 and 2, and o the amino acids can be in the form L, D or DL; the peptides or the composition being intended to promote healing and skin regeneration, and to

augmenter la différenciation cellulaire et la synthèse de protéines de la matrice extracellulaire.  increase cell differentiation and protein synthesis of the extracellular matrix.

Selon un mode de réalisation actuellement préféré de l'invention, le peptide précité est de  According to a currently preferred embodiment of the invention, the above-mentioned peptide is

séquence Lys-Leu-Asp-Ala-Pro-Thr.Lys-Leu-Asp-Ala-Pro-Thr sequence.

La peau est soumise en permanence à de nombreuses agressions de tous ordres qui participent à son vieillissement. L'industrie cosmétique de son côté essaye de développer des molécules ayant une activité sur ce vieillissement. Parmi les grands axes de recherche de ce secteur, la régénération de la peau occupe une part importante. De nombreux produits plus ou moins actifs sont à la disposition des consommateurs afin d'activer la régénération cutanée. Cependant, une partie importante des molécules développées est d'origine animale, principalement bovine. La désaffection ces dix dernières années pour cette catégorie de principes actifs amène les chercheurs à rechercher de nouvelles molécules ayant une activité sur la régénération cutanée. De ce fait, le secteur de la cosmétique est à  The skin is constantly subjected to numerous attacks of all kinds which contribute to its aging. The cosmetic industry for its part is trying to develop molecules having an activity on this aging. Among the major areas of research in this sector, skin regeneration occupies an important part. Many more or less active products are available to consumers in order to activate skin regeneration. However, an important part of the molecules developed is of animal origin, mainly bovine. The disaffection over the past ten years for this category of active ingredients has led researchers to search for new molecules with activity on skin regeneration. As a result, the cosmetics sector is at

la recherche de molécules actives sur la régénération cutanée.  the search for active molecules on skin regeneration.

Or, la demanderesse a trouvé, de façon surprenante et inattendue, qu'une quantité efficace d'un peptide de séquence (AA)n-Leu-Asp-Ala-Pro-(AA)n a une action sur la régénération cutanée. A la connaissance de la demanderesse, il n'a jamais été décrit dans l'art antérieur l'utilisation d'un peptide de séquence (AA)n-Leu-Asp-Ala-Pro-(AA), pour agir sur la  However, the Applicant has found, surprisingly and unexpectedly, that an effective amount of a peptide of sequence (AA) n-Leu-Asp-Ala-Pro- (AA) n has an action on skin regeneration. To the knowledge of the applicant, the use of a peptide of sequence (AA) n-Leu-Asp-Ala-Pro- (AA) has never been described in the prior art, to act on the

régénération de la peau.skin regeneration.

Ainsi, l'invention a pour objet premier l'utilisation pour la préparation d'une composition, d'une quantité efficace de peptides de séquence (AA)aLeu-Asp-Ala-Pro-(AA)n, dans laquelle AA est un quelconque acide aminé ou un de ses dérivés, n est compris entre 0 et 2, et o les acides aminés peuvent être sous la forme L, D ou DL; les peptides ou la  Thus, the primary object of the invention is the use, for the preparation of a composition, of an effective amount of peptides of sequence (AA) aLeu-Asp-Ala-Pro- (AA) n, in which AA is a any amino acid or one of its derivatives, n is between 0 and 2, and o the amino acids may be in the form L, D or DL; peptides or the

composition étant destinés à favoriser la cicatrisation et la régénération cutanée.  composition being intended to promote wound healing and skin regeneration.

Un autre objet de l'invention est l'utilisation pour la préparation d'une composition, d'une quantité efficace de peptides de séquence (AA)n-LeuAsp-Ala-Pro-(AA)n, dans laquelle AA est un quelconque acide aminé ou un de ses dérivés, n est compris entre O et 2, et o les acides aminés peuvent être sous la forme L, D ou DL; les peptides ou la composition étant destinés à augmenter la différenciation cellulaire et la synthèse de protéines de la  Another object of the invention is the use for the preparation of a composition, of an effective amount of peptides of sequence (AA) n-LeuAsp-Ala-Pro- (AA) n, in which AA is any amino acid or one of its derivatives, n is between O and 2, and o the amino acids can be in the form L, D or DL; the peptides or the composition being intended to increase cell differentiation and the synthesis of proteins of the

matrice extra-cellulaire.extracellular matrix.

Selon un mode de réalisation actuellement préféré de l'invention, le peptide précité est de  According to a currently preferred embodiment of the invention, the above-mentioned peptide is

séquence Lys-Leu-Asp-Ala-Pro-Thr.Lys-Leu-Asp-Ala-Pro-Thr sequence.

Le peptide de l'invention peut être modifié par acylation sur sa fonction N-terminale et/ou  The peptide of the invention can be modified by acylation on its N-terminal function and / or

par estérification sur sa fonction C-terminale.  by esterification on its C-terminal function.

Les peptides de l'invention peuvent être obtenus par synthèse chimique ou enzymatique à  The peptides of the invention can be obtained by chemical or enzymatic synthesis with

partir des acides aminés constitutifs ou de leurs dérivés.  from the constituent amino acids or their derivatives.

Les peptides de l'invention peuvent aussi être obtenus par hydrolyse ménagée de protéines naturelles (animale ou végétale), Les peptides de l'invention peuvent enfin être obtenus par biotechnologie (utilisation d'un  The peptides of the invention can also be obtained by careful hydrolysis of natural proteins (animal or vegetable). The peptides of the invention can finally be obtained by biotechnology (use of a

micro-organisme modifié ou non par génie génétique).  microorganism modified or not by genetic engineering).

L'homme de l'art, connaissant le métier de l'extraction et de la purification des peptides et protéines, pourra aisément envisager d'autres procédés d'obtention des peptides décrits par  Those skilled in the art, knowing the trade of extracting and purifying peptides and proteins, can easily envisage other methods of obtaining the peptides described by

la demanderesse.the plaintiff.

Selon un autre mode de réalisation avantageux de l'invention, le peptide précité est préalablement solubilisé dans un ou plusieurs solvants cosmétiquement ou pharmaceutiquement acceptables comme l'eau, le propylène glycol, le butylène glycol, les  According to another advantageous embodiment of the invention, the above-mentioned peptide is dissolved beforehand in one or more cosmetically or pharmaceutically acceptable solvents such as water, propylene glycol, butylene glycol,

diglycols éthoxylés ou propoxylés, l'éthanol, le propanol ou l'isopropanol.  ethoxylated or propoxylated diglycols, ethanol, propanol or isopropanol.

Selon encore un autre mode de réalisation avantageux de l'invention, le peptide précité est préalablement solubilisé dans un vecteur cosmétique ou pharmaceutique comme les liposomes ou adsorbé sur des polymères organiques poudreux, des supports minéraux comme les talcs et bentonites, et plus généralement solubilisé dans, ou fixé sur, tout  According to yet another advantageous embodiment of the invention, the above-mentioned peptide is dissolved beforehand in a cosmetic or pharmaceutical carrier such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally dissolved in , or fixed on, everything

vecteur cosmétiquement ou pharmaceutiquement acceptable.  cosmetically or pharmaceutically acceptable carrier.

Pour donner un ordre de grandeur, dans les compositions cosmétiques ou dermatologiques de la présente invention, le peptide de séquence (AA)1,Leu-Asp-Ala-Pro-(AA)n est utilisé en une concentration représentant de 0, 0005 à 500 ppm (p/p) et préférentiellement en une  To give an order of magnitude, in the cosmetic or dermatological compositions of the present invention, the peptide of sequence (AA) 1, Leu-Asp-Ala-Pro- (AA) n is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably in one

concentration représentant de 0,05 à 50 ppm (p/p).  concentration representing from 0.05 to 50 ppm (w / w).

Pour donner un ordre de grandeur, dans les compositions cosmétiques ou dermatologiques de la présente invention, le peptide de séquence Lys-LeuAsp-Ala-Pro-Thr est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et préférentiellement en une  To give an order of magnitude, in the cosmetic or dermatological compositions of the present invention, the peptide of sequence Lys-LeuAsp-Ala-Pro-Thr is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably in one

concentration représentant de 0,05 à 50 ppm (p/p).  concentration representing from 0.05 to 50 ppm (w / w).

Préférentiellement, les compositions selon la présente invention se présenteront sous une forme galénique adaptée à l'administration par voie topique cutanée, et couvrent toutes les formes cosmétiques ou dermatologiques. Ces compositions doivent donc contenir un milieu cosmétiquement acceptable, c'est-à-dire compatible avec la peau, les poils ou les cheveux. Ces compositions pourront notamment se présenter sous forme de crèmes, émulsions huile-dans-eau, eau-dans-huile ou émulsions multiples, solutions, suspensions,  Preferably, the compositions according to the present invention will be in a dosage form suitable for administration by the topical skin route, and cover all cosmetic or dermatological forms. These compositions must therefore contain a cosmetically acceptable medium, that is to say compatible with the skin, hair or hair. These compositions may in particular be in the form of creams, oil-in-water emulsions, water-in-oil or multiple emulsions, solutions, suspensions,

ou encore poudres, adaptées à une application sur la peau, les lèvres et/ou les cheveux.  or powders, suitable for application to the skin, the lips and / or the hair.

Ces compositions peuvent être plus ou moins fluides et avoir l'aspect d'une crème, d'une lotion, d'un lait, d'un sérum, d'une pommade, d'un gel, d'une pâte ou d'une mousse. Elles peuvent aussi se présenter sous forme solide, comme un stick ou être appliquées sur la peau sous forme d'aérosol. Elles peuvent être utilisées comme produit de soin et/ou comme  These compositions can be more or less fluid and have the appearance of a cream, a lotion, a milk, a serum, an ointment, a gel, a paste or a foam. They can also be in solid form, such as a stick or be applied to the skin in the form of an aerosol. They can be used as a care product and / or as

produit de maquillage de la peau.skin makeup product.

Ces compositions comprennent de façon connue, les adjuvants nécessaires à leur formulation, tels que solvants, épaississants, diluants, antioxydants, colorants, filtres, -4 pigments, charges, conservateurs, parfums, absorbeurs d'odeur. Dans tous les cas, ces adjuvants, ainsi que leurs proportions, seront choisis de manière à ne pas nuire aux propriétés recherchées dans l'invention. Ces adjuvants peuvent par exemple correspondre à  These compositions comprise, in a known manner, the adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, dyes, filters, -4 pigments, fillers, preservatives, perfumes, odor absorbers. In all cases, these adjuvants, as well as their proportions, will be chosen so as not to harm the properties sought in the invention. These adjuvants can for example correspond to

0,01 à 20 % du poids total de la composition.  0.01 to 20% of the total weight of the composition.

Lorsque la composition de l'invention est une émulsion, la phase grasse peut représenter de à 80 % en poids et de préférence de 5 à 50 % en poids par rapport au poids total de la composition. Les émulsionnants et coémulsionnants utilisés dans la composition seront choisis parmi ceux classiquement utilisés dans le domaine considéré. Par exemple, ils peuvent être utilisés en une proportion allant de 0,3 à 30 % en poids, par rapport au poids  When the composition of the invention is an emulsion, the fatty phase can represent from to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition. The emulsifiers and coemulsifiers used in the composition will be chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight, relative to the weight

total de la composition.total of the composition.

Bien entendu, l'homme de métier veillera à choisir les éventuels composés complémentaires, actifs ou non-actifs, et/ou leurs quantités, de telle sorte que les propriétés avantageuses du mélange ne soient pas, ou sensiblement pas, altérées par l'adjonction envisagée. Aussi, un autre objet de l'invention consiste en une composition cosmétique ou dermatologique, caractérisée en ce qu'elle contient, dans un milieu cosmétiquement ou dermatologiquement acceptable, un peptide de séquence (AA)n-Leu-Asp-Ala-Pro-(AA)1, et préférentiellement de séquence Lys-LeuAsp-Ala-Pro-Thr, afin de favoriser la cicatrisation  Of course, the person skilled in the art will take care to choose any additional compounds, active or non-active, and / or their amounts, so that the advantageous properties of the mixture are not, or not substantially, altered by the addition considered. Another object of the invention therefore consists of a cosmetic or dermatological composition, characterized in that it contains, in a cosmetically or dermatologically acceptable medium, a peptide of sequence (AA) n-Leu-Asp-Ala-Pro- (AA) 1, and preferably of Lys-LeuAsp-Ala-Pro-Thr sequence, in order to promote healing

et la régénération cutanée.and skin regeneration.

Un autre objet de l'invention consiste en une composition cosmétique ou dermatologique, caractérisée en ce qu'elle contient, dans un milieu cosmétiquement ou dermatologiquement acceptable, un peptide de séquence (AA)e-Leu-Asp-Ala-Pro-(AA)n et préférentiellement de séquence Lys-Leu-AspAla-Pro-Thr, afin d'augmenter la différenciation cellulaire et la  Another subject of the invention consists of a cosmetic or dermatological composition, characterized in that it contains, in a cosmetically or dermatologically acceptable medium, a peptide of sequence (AA) e-Leu-Asp-Ala-Pro- (AA ) n and preferably of Lys-Leu-AspAla-Pro-Thr sequence, in order to increase cell differentiation and

synthèse de protéines de la matrice extra-cellulaire.  protein synthesis of the extracellular matrix.

Dans les compositions de l'invention, le peptide de séquence (AA)n-LeuAsp-Ala-Pro(AA)n, est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et  In the compositions of the invention, the peptide of sequence (AA) n-LeuAsp-Ala-Pro (AA) n, is used in a concentration representing from 0.0005 to 500 ppm (w / w) and

préférentiellement en une concentration représentant de 0,05 à 50 ppm (p/p).  preferably in a concentration representing from 0.05 to 50 ppm (w / w).

-5 Dans les compositions de l'invention, le peptide de séquence Lys-LeuAsp-Ala-Pro-Thr est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et préférentiellement  -5 In the compositions of the invention, the peptide of sequence Lys-LeuAsp-Ala-Pro-Thr is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably

en une concentration représentant de 0,05 à 50 ppm (p/p).  in a concentration representing from 0.05 to 50 ppm (w / w).

L'invention concerne aussi un procédé cosmétique pour favoriser la cicatrisation et la régénération cutanée, consistant à appliquer, sur la peau, la composition telle que définie précédemment. L'invention concerne enfin un procédé cosmétique pour augmenter l'expression des molécules de la matrice extra-cellulaire, consistant à appliquer, sur la peau ou les cheveux,  The invention also relates to a cosmetic process for promoting wound healing and skin regeneration, consisting in applying the composition as defined above to the skin. The invention finally relates to a cosmetic process for increasing the expression of the molecules of the extra-cellular matrix, consisting in applying, to the skin or the hair,

la composition telle que définie précédemment.  the composition as defined above.

Exemple 1 - Préparation de compositions Ces compositions ont été obtenues par simple mélange des différents composants. Les  Example 1 - Preparation of compositions These compositions were obtained by simple mixing of the various components. The

quantités indiquées sont données en pourcentage de poids.  indicated quantities are given in percentage of weight.

1-Emulsion huile dans eau Phase huileuse: * Montanov 68 (Cetearyl Alcohol and Cetearyl Glucoside) 5.00 % * Huile de Jojoba 5.00 % * Huile de Vaseline 5.00 % * Isopropyl Palmitate 7.00 % Phase aqueuse: * Glycérine 5. 00 % * Allantone 0.10 % * Peptide Lys-Leu-Asp-Ala-Pro-Thr 5 ppm * Sepigel 305 (Polyacrylamide and C 13-14 Isoparaffin and Laureth-7) 0.30 % a Conservateur 0.50 % * Parfum 0.50 % * Eau qsp 100 % - 6 - 2- Gel * Carbopol Ultrez 10 (sol. à 2%) * Triéthanolamine a Peptide Lys-Leu-AspAla-Pro-Thr * Conservateur * EDTA (séquestrant) * Parfum * Eau  1-Oil in water emulsion Oily phase: * Montanov 68 (Cetearyl Alcohol and Cetearyl Glucoside) 5.00% * Jojoba oil 5.00% * Vaseline oil 5.00% * Isopropyl Palmitate 7.00% Aqueous phase: * Glycerin 5. 00% * Allantone 0.10 % * Peptide Lys-Leu-Asp-Ala-Pro-Thr 5 ppm * Sepigel 305 (Polyacrylamide and C 13-14 Isoparaffin and Laureth-7) 0.30% a Preservative 0.50% * Perfume 0.50% * Water qs 100% - 6 - 2- Gel * Carbopol Ultrez 10 (2% sol.) * Triethanolamine a Peptide Lys-Leu-AspAla-Pro-Thr * Preservative * EDTA (sequestrant) * Fragrance * Water

25.00 %25.00%

0.50 %0.50%

0. 1 ppm0.1 ppm

0.20 %0.20%

0.10 %0.10%

0.50 %0.50%

qsp 100 % 3- Lotion * Mono Propylène Glycol * Allantoine a Glycérine * Cetiol HE (PEG-7 Glyceryl Cocoate) * Peptide Lys-Leu-Asp-Ala-Pro-Thr * Conservateur * Parfum * Eau qsp 1.00 0.30 1.00 1.00 1 ppm 0.20 0.50 i i i i i i îi r i t i ii t -7  qsp 100% 3- Lotion * Mono Propylene Glycol * Allantoine a Glycérine * Cetiol HE (PEG-7 Glyceryl Cocoate) * Peptide Lys-Leu-Asp-Ala-Pro-Thr * Preservative * Perfume * Water qs 1.00 0.30 1.00 1.00 1 ppm 0.20 0.50 iiiiii îi riti ii t -7

Claims (17)

REVENDICATIONS 1. Utilisation d'une quantité efficace de peptides de séquence (AA)n-LeuAsp-Ala-Pro(AA)n, dans laquelle AA est un quelconque acide aminé ou un de ses dérivés, n est compris entre 0 et 2, (et o les acides aminés peuvent être sous la forme L, D ou DL) pour la préparation d'une composition, les peptides ou la composition étant destinés à  1. Use of an effective amount of peptides of sequence (AA) n-LeuAsp-Ala-Pro (AA) n, in which AA is any amino acid or one of its derivatives, n is between 0 and 2, ( and o the amino acids can be in the L, D or DL form) for the preparation of a composition, the peptides or the composition being intended for favoriser la cicatrisation et la régénération cutanée.  promote healing and skin regeneration. 2. Utilisation d'une quantité efficace de peptides de séquence (AA)n-LeuAsp-Ala-Pro10 (AA)n, dans laquelle AA est un quelconque acide aminé ou un de ses dérivés, n est compris entre 0 et 2, et o les acides aminés peuvent être sous la forme L, D ou DL pour la préparation d'une composition, les peptides ou la composition étant destinés à  2. Use of an effective amount of peptides of sequence (AA) n-LeuAsp-Ala-Pro10 (AA) n, in which AA is any amino acid or one of its derivatives, n is between 0 and 2, and the amino acids can be in the L, D or DL form for the preparation of a composition, the peptides or the composition being intended for augmenter la différenciation cellulaire et la synthèse de protéines de la matrice extracellulaire.  increase cell differentiation and protein synthesis of the extracellular matrix. 3. Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce  3. Use according to any one of the preceding claims, characterized in that que le peptide est de séquence Lys-Leu-Asp-Ala-Pro-Thr.  that the peptide has the sequence Lys-Leu-Asp-Ala-Pro-Thr. 4. Utilisation selon l'une quelconque des revendications l à 3, caractérisée en ce que le  4. Use according to any one of claims l to 3, characterized in that the peptide est préalablement solubilisé dans un ou plusieurs solvants cosmétiquement ou pharmaceutiquement acceptables comme l'eau, le propylène glycol, le butylène glycol,  peptide is previously dissolved in one or more cosmetically or pharmaceutically acceptable solvents such as water, propylene glycol, butylene glycol, les diglycols éthoxylés ou propoxylés, l'éthanol, le propanol ou l'isopropanol.  ethoxylated or propoxylated diglycols, ethanol, propanol or isopropanol. 5. Utilisation selon l'une quelconque des revendications 1 à 4, caractérisée en ce que le  5. Use according to any one of claims 1 to 4, characterized in that the peptide est préalablement solubilisé dans un vecteur cosmétique ou pharmaceutique comme les liposomes ou adsorbé sur des polymères organiques poudreux, des supports minéraux comme les talcs et bentonites, et plus généralement solubilisé dans, ou fixé  peptide is previously dissolved in a cosmetic or pharmaceutical carrier such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally dissolved in, or fixed sur, tout vecteur cosmétiquement ou pharmaceutiquement acceptable.  on, any cosmetically or pharmaceutically acceptable carrier. 6. Utilisation selon l'une quelconque des revendications l à 5, caractérisée en ce que le  6. Use according to any one of claims l to 5, characterized in that the peptide de séquence (AA)n-Leu-Asp-Ala-Pro-(AA)n est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et préférentiellement en une concentration  peptide of sequence (AA) n-Leu-Asp-Ala-Pro- (AA) n is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably in a concentration représentant de 0,05 à 50 ppm (p/p).  representing from 0.05 to 50 ppm (w / w). 7. Utilisation selon l'une quelconque des revendications 1 à 6, caractérisée en ce que le  7. Use according to any one of claims 1 to 6, characterized in that the peptide de séquence Lys-Leu-Asp-Ala-Pro-Thr est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et préférentiellement en une concentration  peptide of sequence Lys-Leu-Asp-Ala-Pro-Thr is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably in a concentration représentant de 0,05 à 50 ppm (p/p).  representing from 0.05 to 50 ppm (w / w). 8. Composition cosmétique ou dermatologique, caractérisée en ce qu'elle contient, dans un milieu cosmétiquement ou dermatologiquement acceptable, un peptide de séquence  8. Cosmetic or dermatological composition, characterized in that it contains, in a cosmetically or dermatologically acceptable medium, a peptide of sequence (AA)n-Leu-Asp-Ala-Pro-(AA)n et préférentiellement de séquence Lys-Leu-AspAlaPro-Thr, afin de favoriser la cicatrisation et la régénération cutanée.  (AA) n-Leu-Asp-Ala-Pro- (AA) n and preferably of sequence Lys-Leu-AspAlaPro-Thr, in order to promote healing and skin regeneration. 9. Composition cosmétique ou dermatologique, caractérisée en ce qu'elle contient, dans un milieu cosmétiquement ou dermatologiquement acceptable, un peptide de séquence (AA)n-Leu-Asp-Ala-Pro-(AA)n et préférentiellement de séquence Lys-Leu-Asp-AlaPro-Thr, afin d'augmenter la différenciation cellulaire et la synthèse de protéines de la  9. Cosmetic or dermatological composition, characterized in that it contains, in a cosmetically or dermatologically acceptable medium, a peptide of sequence (AA) n-Leu-Asp-Ala-Pro- (AA) n and preferably of sequence Lys- Leu-Asp-AlaPro-Thr, to increase cell differentiation and protein synthesis of the matrice extra-cellulaire.extracellular matrix. 10. Composition selon l'une quelconque des revendications 8 ou 9, caractérisée en ce que  10. Composition according to any one of claims 8 or 9, characterized in that le peptide de séquence (AA)n-Leu-Asp-Ala-Pro-(AA)n est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et préférentiellement en une concentration  the peptide of sequence (AA) n-Leu-Asp-Ala-Pro- (AA) n is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably in a concentration représentant de 0,05 à 50 ppm (p/p).  representing from 0.05 to 50 ppm (w / w). 11. Composition selon l'une quelconque des revendications 8 à 10, caractérisée en ce que  11. Composition according to any one of claims 8 to 10, characterized in that le peptide de séquence Lys-Leu-Asp-Ala-Pro-Thr est utilisé en une concentration représentant de 0,0005 à 500 ppm (p/p) et préférentiellement en une concentration  the peptide of sequence Lys-Leu-Asp-Ala-Pro-Thr is used in a concentration representing from 0.0005 to 500 ppm (w / w) and preferably in a concentration représentant de 0,05 à 50 ppm (p/p).  representing from 0.05 to 50 ppm (w / w). 12. Composition cosmétique selon l'une quelconque des revendications 8 à 11 caractérisée  12. Cosmetic composition according to any one of claims 8 to 11 characterized en ce que le peptide est modifié par acylation sur sa fonction Nterminale et/ou par  in that the peptide is modified by acylation on its Nterminal function and / or by estérification sur sa fonction C-terminale.  esterification on its C-terminal function. 13. Composition cosmétique selon l'une quelconque des revendications 8 à 12, caractérisée  13. Cosmetic composition according to any one of claims 8 to 12, characterized en ce que le peptide est obtenu par synthèse chimique ou enzymatique à partir des  in that the peptide is obtained by chemical or enzymatic synthesis from acides aminés constitutifs ou de leurs dérivés.  constituent amino acids or their derivatives. -9-9 14. Composition cosmétique selon l'une quelconque des revendications 8 à 12, caractérisée  14. Cosmetic composition according to any one of claims 8 to 12, characterized en ce que le peptide est obtenu par hydrolyse ménagée de protéines naturelles.  in that the peptide is obtained by gentle hydrolysis of natural proteins. 15. Composition cosmétique selon l'une quelconque des revendications 8 à 12, caractérisée  15. Cosmetic composition according to any one of claims 8 to 12, characterized en ce que le peptide est obtenu par biotechnologie.  in that the peptide is obtained by biotechnology. 16. Procédé cosmétique pour favoriser la cicatrisation et la régénération cutanée, consistant  16. Cosmetic process to promote healing and skin regeneration, consisting à appliquer, sur la peau, la composition selon l'une quelconque des revendications 8 à  applying, to the skin, the composition according to any one of claims 8 to 15.15. 17. Procédé cosmétique pour augmenter l'expression des molécules de la matrice extracellulaire, consistant à appliquer, sur la peau, la composition selon l'une quelconque des  17. Cosmetic method for increasing the expression of the molecules of the extracellular matrix, consisting in applying, to the skin, the composition according to any one of revendications 8 à 15.claims 8 to 15.
FR0208285A 2002-07-03 2002-07-03 USE OF PEPTIDES TO PROMOTE SKIN REGENERATION Expired - Lifetime FR2841781B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0208285A FR2841781B1 (en) 2002-07-03 2002-07-03 USE OF PEPTIDES TO PROMOTE SKIN REGENERATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0208285A FR2841781B1 (en) 2002-07-03 2002-07-03 USE OF PEPTIDES TO PROMOTE SKIN REGENERATION

Publications (2)

Publication Number Publication Date
FR2841781A1 true FR2841781A1 (en) 2004-01-09
FR2841781B1 FR2841781B1 (en) 2005-12-16

Family

ID=29725101

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0208285A Expired - Lifetime FR2841781B1 (en) 2002-07-03 2002-07-03 USE OF PEPTIDES TO PROMOTE SKIN REGENERATION

Country Status (1)

Country Link
FR (1) FR2841781B1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007057448A1 (en) * 2005-11-21 2007-05-24 L'oréal Topical compositions for promoting homeostasis of the skin
FR2893502A1 (en) * 2005-11-21 2007-05-25 Oreal Cosmetic skincare method, useful e.g. for combating skin ageing, comprises simultaneous/sequential application of composition comprising agent increasing expression of mechanoreceptors in cells, and device
WO2016162343A1 (en) 2015-04-09 2016-10-13 Isp Investments Inc. Hydroalcoholic extract of schinus molle, cosmetic compositions comprising the same and cosmetic uses thereof
WO2017084958A1 (en) 2015-11-17 2017-05-26 ISP Investments LLC. Process for obtaining an aqueous extract enriched with small rnas from a plant material and extracts resulting from the process
WO2018048864A1 (en) 2016-09-07 2018-03-15 Isp Investments Llc Aqueous extract of prunus persica and process for preparing the same
WO2018146066A1 (en) 2017-02-09 2018-08-16 ISP Investments LLC. Marsdenia cundurango creeper extracts, cosmetic compositions comprising them and cosmetic uses of same
WO2018189194A1 (en) 2017-04-14 2018-10-18 ISP Investments LLC. Cosmetic preparation containing white truffle extract and cosmetic method thereof
WO2018206322A1 (en) 2017-05-12 2018-11-15 ISP Investments LLC. Method for obtaining a small-rna-enriched aqueous extract of anethum graveolens
WO2019149864A1 (en) 2018-01-30 2019-08-08 Isp Investments Llc Myrciaria dubia fruit extracts rich in organic acids, cosmetic compositions comprising same and cosmetic uses thereof
FR3091993A1 (en) 2019-01-29 2020-07-31 Isp Investments Llc PROCESS FOR OBTAINING AN EXTRACT OF PATCHOULI LEAVES AND ITS COSMETIC USES
FR3106754A1 (en) 2020-02-04 2021-08-06 Isp Investments Llc PROCESS FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS INCLUDING SUCH EXTRACT AND THEIR COSMETIC USES
WO2021233672A1 (en) 2020-05-19 2021-11-25 ISP Investments LLC. Method for obtaining an extract of sandalwood, compositions comprising same and cosmetic uses thereof
WO2022043840A1 (en) 2020-08-25 2022-03-03 Isp Investments Llc Compositions and methods for improving the appearance of the skin
WO2022106718A1 (en) 2020-11-23 2022-05-27 Isp Investments Llc Method for obtaining aqueous extracts of tea leaves, compositions comprising such extracts and cosmetic uses thereof
US11478418B2 (en) 2016-03-08 2022-10-25 Isp Investments Llc Fat and/or wax activated by means of the water-insoluble fraction of Carica papaya sap
WO2023001812A1 (en) 2021-07-22 2023-01-26 Isp Investments Llc Black tea leaf extract, compositions comprising same and cosmetic uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002537A1 (en) * 1990-08-01 1992-02-20 Universite Paris Val De Marne Method for preparing a peptide having growth factor activity, a product thereby obtained, and uses thereof as a drug
WO2000015188A1 (en) * 1998-09-15 2000-03-23 Sederma S.A. Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
WO2000077042A2 (en) * 1999-06-15 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Parathyroid hormone receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002537A1 (en) * 1990-08-01 1992-02-20 Universite Paris Val De Marne Method for preparing a peptide having growth factor activity, a product thereby obtained, and uses thereof as a drug
WO2000015188A1 (en) * 1998-09-15 2000-03-23 Sederma S.A. Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
WO2000077042A2 (en) * 1999-06-15 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Parathyroid hormone receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOYANO, JOSE V. ET AL: "Fibronectin Type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated.alpha.4.beta.1 and.alpha.4.beta.7 integrins", JOURNAL OF BIOLOGICAL CHEMISTRY (1997), 272(40), 24832-24836, XP002218954 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007057448A1 (en) * 2005-11-21 2007-05-24 L'oréal Topical compositions for promoting homeostasis of the skin
FR2893501A1 (en) * 2005-11-21 2007-05-25 Oreal Topical composition, useful e.g., to increase thickness, radiant and density and/or improve firmness, elasticity and/or tonicity of skin, comprises tensor and peptide increasing expression of mechanoreceptors in cells of skin
FR2893502A1 (en) * 2005-11-21 2007-05-25 Oreal Cosmetic skincare method, useful e.g. for combating skin ageing, comprises simultaneous/sequential application of composition comprising agent increasing expression of mechanoreceptors in cells, and device
WO2007057449A3 (en) * 2005-11-21 2007-07-26 Oreal Cosmetic skincare method employing mechanical stresses
WO2016162343A1 (en) 2015-04-09 2016-10-13 Isp Investments Inc. Hydroalcoholic extract of schinus molle, cosmetic compositions comprising the same and cosmetic uses thereof
WO2017084958A1 (en) 2015-11-17 2017-05-26 ISP Investments LLC. Process for obtaining an aqueous extract enriched with small rnas from a plant material and extracts resulting from the process
US11021505B2 (en) 2015-11-17 2021-06-01 Isp Investments Llc Aqueous extract enriched with small RNAs and compositions comprising such extracts and to their cosmetic uses
US11478418B2 (en) 2016-03-08 2022-10-25 Isp Investments Llc Fat and/or wax activated by means of the water-insoluble fraction of Carica papaya sap
WO2018048864A1 (en) 2016-09-07 2018-03-15 Isp Investments Llc Aqueous extract of prunus persica and process for preparing the same
WO2018146066A1 (en) 2017-02-09 2018-08-16 ISP Investments LLC. Marsdenia cundurango creeper extracts, cosmetic compositions comprising them and cosmetic uses of same
WO2018189194A1 (en) 2017-04-14 2018-10-18 ISP Investments LLC. Cosmetic preparation containing white truffle extract and cosmetic method thereof
WO2018206322A1 (en) 2017-05-12 2018-11-15 ISP Investments LLC. Method for obtaining a small-rna-enriched aqueous extract of anethum graveolens
WO2018206751A1 (en) 2017-05-12 2018-11-15 Isp Investments Llc Composition comprising a small-rna-enriched aqueous extract of anethum graveolens, and cosmetic uses thereof
WO2019149864A1 (en) 2018-01-30 2019-08-08 Isp Investments Llc Myrciaria dubia fruit extracts rich in organic acids, cosmetic compositions comprising same and cosmetic uses thereof
FR3091993A1 (en) 2019-01-29 2020-07-31 Isp Investments Llc PROCESS FOR OBTAINING AN EXTRACT OF PATCHOULI LEAVES AND ITS COSMETIC USES
WO2020156981A1 (en) 2019-01-29 2020-08-06 ISP Investments LLC. Method for obtaining an extract of patchouli leaves and cosmetic uses thereof
FR3106754A1 (en) 2020-02-04 2021-08-06 Isp Investments Llc PROCESS FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS INCLUDING SUCH EXTRACT AND THEIR COSMETIC USES
WO2021156104A1 (en) 2020-02-04 2021-08-12 ISP Investments LLC. Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses
WO2021233672A1 (en) 2020-05-19 2021-11-25 ISP Investments LLC. Method for obtaining an extract of sandalwood, compositions comprising same and cosmetic uses thereof
FR3110425A1 (en) 2020-05-19 2021-11-26 ISP Investments LLC. PROCESS FOR OBTAINING A SANDALWOOD EXTRACT, COMPOSITIONS CONTAINING IT AND ITS COSMETIC USES
WO2022043840A1 (en) 2020-08-25 2022-03-03 Isp Investments Llc Compositions and methods for improving the appearance of the skin
WO2022106718A1 (en) 2020-11-23 2022-05-27 Isp Investments Llc Method for obtaining aqueous extracts of tea leaves, compositions comprising such extracts and cosmetic uses thereof
FR3116438A1 (en) 2020-11-23 2022-05-27 ISP Investments LLC. METHOD FOR OBTAINING AQUEOUS EXTRACTS FROM TEA LEAVES, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES
WO2023001812A1 (en) 2021-07-22 2023-01-26 Isp Investments Llc Black tea leaf extract, compositions comprising same and cosmetic uses thereof
FR3125425A1 (en) 2021-07-22 2023-01-27 Isp Investments Llc EXTRACT OF BLACK TEA LEAVES, COMPOSITIONS COMPRISING THEM AND COSMETIC USES THEREOF

Also Published As

Publication number Publication date
FR2841781B1 (en) 2005-12-16

Similar Documents

Publication Publication Date Title
EP1406589B1 (en) Cosmetic or dermatological use of peptides for promoting adhesion between skin cells
FR2841781A1 (en) Cosmetic or dermatological composition, e.g. for promoting wound healing and skin regeneration, comprises a peptide including a Leu-Asp-Ala-Pro sequence
WO2000040611A1 (en) Slimming cosmetic compositions
EP1490092B1 (en) Cosmetic or pharmaceutical composition containing peptides
FR2854897A1 (en) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR REDUCING THE SIGNS OF SKIN AGING.
CA2185932C (en) Use of a least one peptide in a cosmetic composition or for the preparation of a drug
FR2514643A1 (en) COPPER LANOLATE AND ANTI-ACNE COSMETIC COMPOSITIONS CONTAINING THE SAME
FR2718639A1 (en) Cosmetic and / or dermatological composition containing a tri (alpha-hydroxyacylate) of glycerol as the sole precursor of glycerol.
WO2003008438A2 (en) Cosmetic or dermatological use of peptides for promoting adhesion between skin cells
FR2846883A1 (en) Cosmetic, dermatological and/or pharmaceutical compositions, especially for combating skin aging and/or protecting skin, containing peptide including arginine-glycine-serine moiety as active agent
EP1575605B1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
FR2722100A1 (en) PERVENCHE SEED EXTRACT AND COMPOSITION CONTAINING SAME
FR2850579A1 (en) Use of di-esters or mono-esters of cinnamic acid and derivatives of vitamin C as donors of nitric oxide in the treatment of skin, mucous membranes and scalp
FR2770228A1 (en) Proanthocyanidine oligomer concentrates obtained by fermenting Schinopsis lorenzii extract
FR2850578A1 (en) Use of N-benzyl or N-pyridylmethyl iminodiacetic acid derivatives as NO synthesis stimulant for treatment of conditions affecting keratinaceous and mucosal tissue
EP1414404B1 (en) Use of date stone extract for treating the signs of aging skin
CA2166517C (en) Cosmetic or dermatologic composition containing at least a ceramide 6
FR2827171A1 (en) Use of an enzymatic hydrolysate of salmon eggs for preventing or treating the effects of aging caused by physiology or sunlight
WO2008145855A1 (en) Pharmaceutical and/or cosmetic composition containing a cytochrome c-activating active ingredient
WO2003002085A1 (en) Use of purified, water-soluble xylans extracted from palmaria
FR2723314A1 (en) Skin compsns. contg. Centaurium and Siegesbeckia orientalis extracts
EP1367989B1 (en) Cosmetic composition comprising a mixture and its use to reduce secretion of sebum
FR2844200A1 (en) Cosmetic and/or pharmaceutical compositions for treating keratin substrates, e.g. skin or hair, containing dephenolated sunflower protein hydrolyzates having e.g. moisturizing, antioxidant and antiaging effects
FR2852841A1 (en) COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AMINO ACIDS, USES AND METHODS OF TREATMENT
EP2150266A1 (en) Pharmaceutical and/or cosmetic composition containing an active ingredient which is antioxidant and which activates cell energy

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20